| Trial ID: | L6220 |
| Source ID: | NCT02150707
|
| Associated Drug: |
Dipeptidyl-Peptidase Iv Inhibitors
|
| Title: |
The Differential Effects of Diabetes Therapy on Inflammation
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetic Nephropathy|Type 2 Diabetes
|
| Interventions: |
DRUG: Dipeptidyl-Peptidase IV Inhibitors|DRUG: Glucagon-Like Peptide 1
|
| Outcome Measures: |
Primary: Monocyte:chemoattractant protein 1 (MCP-1):creatinine ratio, 6 months | Secondary: Albumin:creatinine ratio, 6 months
|
| Sponsor/Collaborators: |
Sponsor: University College Dublin | Collaborators: Irish Endocrine Society|Royal College of Physicians|Merck Sharp & Dohme LLC|Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
17
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2014-05
|
| Completion Date: |
2015-12
|
| Results First Posted: |
|
| Last Update Posted: |
2016-05-18
|
| Locations: |
Mater Misericordiae University Hospital, Dublin, Dublin 7, Ireland
|
| URL: |
https://clinicaltrials.gov/show/NCT02150707
|
